A Phase II Study of the Farnesyltransferase Inhibitor ZARNESTRA (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults With Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00045396

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:23.627624+00:00

Published At

2013-01-09T00:00:00+00:00

Record Updated At

2013-01-09

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "de Novo Myelodysplastic Syndromes", "Secondary Myelodysplastic Syndromes"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2013-01-09"

protocolSection.identificationModule.nctId

"NCT00045396"

protocolSection.identificationModule.officialTitle

"A Phase II Study of the Farnesyltransferase Inhibitor ZARNESTRA (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults With Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS)."

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Adult Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
• de Novo Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
• Secondary Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.